Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 10/2018

Open Access 01-10-2018 | Original Research

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample

Authors: Marco Calabrò, Laura Mandelli, Concetta Crisafulli, Soo-Jung Lee, Tae-Youn Jun, Sheng-Min Wang, Ashwin A. Patkar, Prakash S. Masand, Francesco Benedetti, Changsu Han, Chi-Un Pae, Alessandro Serretti

Published in: Advances in Therapy | Issue 10/2018

Login to get access

Abstract

Introduction

Mood disorders are common and disabling disorders. Despite the availability of over 100 psychotropic compounds, only one-third of patients benefit from first-line treatments. Over the past 20 years, many studies have focused on the biological factors modulating disease risk and response to treatments, but with still inconclusive data. In order to improve our current knowledge, in this study, we investigated the role of a set of genes involved in different pathways (neurotransmission, neuroplasticity, circadian rhythms, transcription factors, signal transduction and cellular metabolism) in the treatment outcome of major depressive disorder (MDD) and bipolar disorder (BD) after naturalistic pharmacological treatment.

Methods

Totals of 242 MDD, 132 BD patients and 326 healthy controls of Asian ethnicity (Koreans) were genotyped for polymorphisms within 19 genes. Response and remission after 6–8 weeks of treatment with antidepressants and mood stabilizers were evaluated. In secondary analyses, genetic associations with disease risk and some disease-associated features (age of onset, suicide attempt and psychotic BD) were also tested.

Results

None of the variants within the investigated genes was significantly associated with treatment outcomes. Some marginal association (uncorrected p < 0.01) was observed for HTR2A, BDNF, CHL1, RORA and HOMER1 SNPs. In secondary analyses, HTR2A (rs643627, p = 0.002) and CHL1 (rs4003413, p = 0.002) were found associated with risk for BD, HOMER1 (rs6872497, p = 0.002) with lifetime history of suicide attempt in patients, and RORA with early onset and presence of psychotic features in BD. Marginal results were also observed for ST8SIA2 and COMT.

Discussion

Despite limitations linked to multiple testing on small samples, methodological shortcomings and small significance of the findings, this study may support the involvement of some candidate genes in the outcomes of treatments for mood disorders, as well as in BD risk and other disease features.
Appendix
Available only for authorised users
Literature
1.
Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, Ustun TB, Wang PS. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc. 2009;18:23–33.CrossRefPubMedPubMedCentral
2.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.CrossRefPubMed
3.
Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163:217–24.CrossRefPubMed
4.
Dedic N, Pohlmann ML, Richter JS, Mehta D, Czamara D, Metzger MW, Dine J, Bedenk BT, Hartmann J, Wagner KV, Jurik A, Almli LM, Lori A, Moosmang S, Hofmann F, Wotjak CT, Rammes G, Eder M, Chen A, Ressler KJ, Wurst W, Schmidt MV, Binder EB, Deussing JM. Cross-disorder risk gene CACNA1C differentially modulates susceptibility to psychiatric disorders during development and adulthood. Mol Psychiatry 2018; 23(3):533–543.CrossRefPubMedPubMedCentral
5.
Rao S, Yao Y, Zheng C, Ryan J, Mao C, Zhang F, Meyre D, Xu Q. Common variants in CACNA1C and MDD susceptibility: a comprehensive meta-analysis. Am J Med Genet B 2016;171:896–903.CrossRef
6.
He K, An Z, Wang Q, Li T, Li Z, Chen J, Li W, Wang T, Ji J, Feng G, Lin H, Yi Q, Shi Y. CACNA1C, schizophrenia and major depressive disorder in the Han Chinese population. Br J Psychiatry. 2014;204:36–9.CrossRefPubMed
7.
8.
Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W, Smit JH, de Jonge P, Penninx BW. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry. 2012;2:e79.CrossRefPubMedPubMedCentral
9.
Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013;14:135–51.CrossRefPubMed
10.
Cross-Disorder Group of the Psychiatric Genomics. C: identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371–9.CrossRef
11.
Gershon ES, Pearlson G, Keshavan MS, Tamminga C, Clementz B, Buckley PF, Alliey-Rodriguez N, Liu C, Sweeney JA, Keedy S, Meda SA, Tandon N, Shafee R, Bishop JR, Ivleva EI. Genetic analysis of deep phenotyping projects in common disorders. Schizophr Res. 2018;195:51–7.CrossRefPubMed
12.
Calati R, Crisafulli C, Balestri M, Serretti A, Spina E, Calabro M, Sidoti A, Albani D, Massat I, Hofer P, Amital D, Juven-Wetzler A, Kasper S, Zohar J, Souery D, Montgomery S, Mendlewicz J. Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:271–8.CrossRefPubMed
13.
Fabbri C, Crisafulli C, Gurwitz D, Stingl J, Calati R, Albani D, Forloni G, Calabro M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Girolamo GD, Serretti A. Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J. 2015;15:538–48.CrossRefPubMed
14.
15.
Marsden WN. Synaptic plasticity in depression: molecular, cellular and functional correlates. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:168–84.CrossRefPubMed
16.
Mallei A, Failler M, Corna S, Racagni G, Mathe AA, Popoli M. Synaptoproteomic analysis of a rat gene-environment model of depression reveals involvement of energy metabolism and cellular remodeling pathways. Int J Neuropsychopharmacol 2015;18(3):pyu067.CrossRefPubMed
17.
Fabbri C, Marsano A, Albani D, Chierchia A, Calati R, Drago A, Crisafulli C, Calabro M, Kasper S, Lanzenberger R, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J. 2014;14:463–72.CrossRefPubMed
18.
Niciu MJ, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr. Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. CNS Spectr. 2013;18:242–51.CrossRefPubMedPubMedCentral
19.
D’Addario C, Palazzo MC, Benatti B, Grancini B, Pucci M, Di Francesco A, Camuri G, Galimberti D, Fenoglio C, Scarpini E, Altamura AC, Maccarrone M, Dell’Osso B. Regulation of gene transcription in bipolar disorders: role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:314–21.CrossRefPubMed
20.
Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb Exp Pharmacol. 2014;220:223–50.CrossRefPubMed
21.
Dityatev A, Bukalo O, Schachner M. Modulation of synaptic transmission and plasticity by cell adhesion and repulsion molecules. Neuron Glia Biol. 2008;4:197–209.CrossRefPubMed
22.
Nacher J, Guirado R, Varea E, Alonso-Llosa G, Rockle I, Hildebrandt H. Divergent impact of the polysialyltransferases ST8SiaII and ST8SiaIV on polysialic acid expression in immature neurons and interneurons of the adult cerebral cortex. Neuroscience. 2010;167:825–37.CrossRefPubMed
23.
Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007;14:2053–69.CrossRefPubMed
24.
Antypa N, Drago A, Serretti A. The role of COMT gene variants in depression: bridging neuropsychological, behavioral and clinical phenotypes. Neurosci Biobehav Rev. 2013;37:1597–610.CrossRefPubMed
25.
de Bartolomeis A, Latte G, Tomasetti C, Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol Neurobiol. 2014;49:484–511.CrossRefPubMed
26.
Partonen T. Clock gene variants in mood and anxiety disorders. J Neural Transm (Vienna). 2012;119:1133–45.CrossRef
27.
Fabbri C, Crisafulli C, Calati R, Albani D, Forloni G, Calabro M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. Eur Arch Psychiatry Clin Neurosci. 2017;267:723–35.CrossRefPubMed
28.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 (quiz 34–57).PubMed
29.
Mandelli L, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU, Serretti A. The impact of a single nucleotide polymorphism in SIGMAR1 on depressive symptoms in major depressive disorder and bipolar disorder. Adv Ther. 2017;34:713–24.CrossRefPubMed
30.
Calabro M, Mandelli L, Crisafulli C, Sidoti A, Jun TY, Lee SJ, Han C, Patkar AA, Masand PS, Pae CU, Serretti A. Genes involved in neurodevelopment, neuroplasticity, and bipolar disorder: CACNA1C, CHRNA1, and MAPK1. Neuropsychobiology. 2016;74:159–68.CrossRefPubMed
31.
Chiesa A, Pae CU, Porcelli S, Han C, Lee SJ, Patkar AA, Park MH, Jun TY, Serretti A. DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder. J Int Med Res. 2012;40:258–65.CrossRefPubMed
32.
Crisafulli C, Shim DS, Andrisano C, Pae CU, Chiesa A, Han C, Patkar AA, Lee SJ, Serretti A, De Ronchi D. Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. Psychiatry Res. 2012;198:39–46.CrossRefPubMed
33.
Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Serretti A, De Ronchi D. Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology. 2012;65:1–11.CrossRefPubMed
34.
Woo YS, Bahk WM, Pae CU, Jeong JH, Koo BH, Jon DI, Lee JG, Kim MD. Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. Asia-Pacific Psychiatry. 2014;6:334–41.CrossRefPubMed
35.
36.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.CrossRefPubMed
37.
Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S. European Group for the Study of Resistant Depression (GSRD)—where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453–68.CrossRefPubMed
38.
Calabrò M, Mandelli L, Crisafulli C, Colombo R, Janiri L, Serretti A: ZNF804A rs1344706 and rs75957593 cross-diagnostic influence on psychosis and treatment improvement in Mood Disorders. submitted. (unpublished)
39.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMed
40.
Shaffer JP. Multiple hypothesis testing. Annu Rev Psychol. 1995;46:561–84.CrossRef
41.
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.CrossRefPubMed
42.
Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, Souza RP, van den Oord EJ. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med. 2012;42:1151–62.CrossRefPubMed
43.
Morag A, Pasmanik-Chor M, Oron-Karni V, Rehavi M, Stingl JC, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics. 2011;12:171–84.CrossRefPubMed
44.
Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M, Stingl JC, Gurwitz D. Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics. 2012;13:1129–39.CrossRefPubMed
45.
Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N, Gurwitz D. Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl Psychiatry. 2013;3:e313.CrossRefPubMedPubMedCentral
46.
Oved K, Farberov L, Gilam A, Israel I, Haguel D, Gurwitz D, Shomron N. MicroRNA-mediated regulation of ITGB3 and CHL1 is implicated in SSRI action. Front Mol Neurosci. 2017;10:355.CrossRefPubMedPubMedCentral
47.
Probst-Schendzielorz K, Scholl C, Efimkina O, Ersfeld E, Viviani R, Serretti A, Fabbri C, Gurwitz D, Lucae S, Ising M, Paul AM, Lehmann ML, Steffens M, Crisafulli C, Calabro M, Holsboer F, Stingl J. CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich antidepressant response signature (MARS) study. Pharmacogenomics. 2015;16:689–701.CrossRefPubMed
48.
Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, Seif I, Robert P, David D, Guilloux JP, Gardier AM, Verstuyft C, Becquemont L, Corruble E, Guiard BP. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: a translational approach. Neuropharmacology. 2016;105:142–53.CrossRefPubMed
49.
Noor A, Lionel AC, Cohen-Woods S, Moghimi N, Rucker J, Fennell A, Thiruvahindrapuram B, Kaufman L, Degagne B, Wei J, Parikh SV, Muglia P, Forte J, Scherer SW, Kennedy JL, Xu W, McGuffin P, Farmer A, Strauss J, Vincent JB. Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. Am J Med Genet B. 2014;165B:303–13.CrossRef
50.
Abdolmaleky HM, Yaqubi S, Papageorgis P, Lambert AW, Ozturk S, Sivaraman V, Thiagalingam S. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res. 2011;129:183–90.CrossRefPubMed
51.
Ghadirivasfi M, Nohesara S, Ahmadkhaniha HR, Eskandari MR, Mostafavi S, Thiagalingam S, Abdolmaleky HM. Hypomethylation of the serotonin receptor type-2A Gene (HTR2A) at T102C polymorphic site in DNA derived from the saliva of patients with schizophrenia and bipolar disorder. Am J Med Genet B. 2011;156B:536–45.CrossRef
52.
Malone KM, Ellis SP, Currier D, John Mann J. Platelet 5-HT2A receptor subresponsivity and lethality of attempted suicide in depressed in-patients. Int J Neuropsychopharmacol. 2007;10:335–43.CrossRefPubMed
53.
Smith RM, Papp AC, Webb A, Ruble CL, Munsie LM, Nisenbaum LK, Kleinman JE, Lipska BK, Sadee W. Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry. 2013;73:546–54.CrossRefPubMed
54.
Lin JY, Jiang MY, Kan ZM, Chu Y. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430–8.CrossRefPubMed
55.
Zhao X, Sun L, Sun YH, Ren C, Chen J, Wu ZQ, Jiang YH, Lv XL. Association of HTR2A T102C and A-1438G polymorphisms with susceptibility to major depressive disorder: a meta-analysis. Neurol Sci. 2014;35:1857–66.CrossRefPubMed
56.
Buoli M, Serati M, Grassi S, Pergoli L, Cantone L, Altamura AC, Bollati V. The role of clock genes in the etiology of Major Depressive Disorder: Special Section on “Translational and Neuroscience Studies in Affective Disorders”. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J Affect Disord. 2018;234:351–7.CrossRefPubMed
57.
Melo MC, Garcia RF, Linhares Neto VB, Sa MB, de Mesquita LM, de Araujo CF, de Bruin VM. Sleep and circadian alterations in people at risk for bipolar disorder: a systematic review. J Psychiatr Res. 2016;83:211–9.CrossRefPubMed
58.
Johansson AS, Owe-Larsson B, Hetta J, Lundkvist GB. Altered circadian clock gene expression in patients with schizophrenia. Schizophr Res. 2016;174:17–23.CrossRefPubMed
59.
Serretti A, Benedetti F, Mandelli L, Calati R, Caneva B, Lorenzi C, Fontana V, Colombo C, Smeraldi E. Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Res. 2008;158:132–40.CrossRefPubMed
60.
McGrath CL, Glatt SJ, Sklar P, Le-Niculescu H, Kuczenski R, Doyle AE, Biederman J, Mick E, Faraone SV, Niculescu AB, Tsuang MT. Evidence for genetic association of RORB with bipolar disorder. BMC Psychiatry. 2009;9:70.CrossRefPubMedPubMedCentral
61.
Porcelli S, Lee SJ, Han C, Patkar AA, Albani D, Jun TY, Pae CU, Serretti A. Hot genes in Schizophrenia: how clinical datasets could help to refine their role. J Mol Neurosci. 2018;64:273–86.CrossRefPubMed
62.
Lai YC, Kao CF, Lu ML, Chen HC, Chen PY, Chen CH, Shen WW, Wu JY, Lu RB, Kuo PH. Investigation of associations between NR1D1, RORA and RORB genes and bipolar disorder. PLoS ONE. 2015;10:e0121245.CrossRefPubMedPubMedCentral
63.
Yeim S, Boudebesse C, Etain B. Belliviera F [Circadian markers and genes in bipolar disorder]. Encephale. 2015;41:S38–44.CrossRefPubMed
64.
Hennings JM, Uhr M, Klengel T, Weber P, Putz B, Touma C, Czamara D, Ising M, Holsboer F, Lucae S. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transl Psychiatry. 2015;5:e538.CrossRefPubMedPubMedCentral
65.
Geoffroy PA, Etain B, Lajnef M, Zerdazi EH, Brichant-Petitjean C, Heilbronner U, Hou L, Degenhardt F, Rietschel M, McMahon FJ, Schulze TG, Jamain S, Marie-Claire C, Bellivier F. Circadian genes and lithium response in bipolar disorders: associations with PPARGC1A (PGC-1alpha) and RORA. Genes Brain Behav. 2016;15:660–8.CrossRefPubMed
66.
Wagner KV, Hartmann J, Mangold K, Wang XD, Labermaier C, Liebl C, Wolf M, Gassen NC, Holsboer F, Rein T, Muller MB, Schmidt MV. Homer1 mediates acute stress-induced cognitive deficits in the dorsal hippocampus. J Neurosci. 2013;33:3857–64.CrossRefPubMed
67.
Rao S, Leung CS, Lam MH, Wing YK, Waye MM, Tsui SK. Resequencing three candidate genes discovers seven potentially deleterious variants susceptibility to major depressive disorder and suicide attempts in Chinese. Gene. 2017;603:34–41.CrossRefPubMed
68.
Rao S, Lam MH, Yeung VS, Wing YK, Waye MM. Association of HOMER1 rs2290639 with suicide attempts in Hong Kong Chinese and the potentially functional role of this polymorphism. Springerplus. 2016;5:767.CrossRefPubMedPubMedCentral
69.
Benedetti F, Poletti S, Locatelli C, Mazza E, Lorenzi C, Vitali A, Riberto M, Brioschi S, Vai B, Bollettini I, Melloni E, Aggio V, Falini A, De Bartolomeis A, Colombo C. A Homer 1 gene variant influences brain structure and function, lithium effects on white matter, and antidepressant response in bipolar disorder: a multimodal genetic imaging study. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:88–95.CrossRefPubMed
70.
Perche O, Menuet A, Marcos M, Liu L, Paris A, Utami KH, Kervran D, Cacheux V, Laudier B, Briault S. Combined deletion of two Condensin II system genes (NCAPG2 and MCPH1) in a case of severe microcephaly and mental deficiency. Eur J Med Genet. 2013;56:635–41.CrossRefPubMed
71.
Calabro M, Porcelli S, Crisafulli C, Wang SM, Lee SJ, Han C, Patkar AA, Masand PS, Albani D, Raimondi I, Forloni G, Bin S, Mattiaccio A, Mantovani V, Jun TY, Pae CU, Serretti A. Genetic variants within key nodes of the cascade of antipsychotic mechanisms: effects on antipsychotic response and Schizophrenia psychopathology in a naturalistic treatment setting in two independent Korean and Italian samples. Adv Ther. 2017;34:1482–97.CrossRefPubMed
72.
Wang M, Ma Y, Yuan W, Su K, Li MD. Meta-analysis of the COMT Val158Met polymorphism in major depressive disorder: effect of ethnicity. J Neuroimmune Pharmacol. 2016;11:434–45.CrossRefPubMed
73.
Gatt JM, Burton KL, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J Psychiatr Res. 2015;60:1–13.CrossRefPubMed
74.
Yang SY, Huh IS, Baek JH, Cho EY, Choi MJ, Ryu S, Kim JS, Park T, Ha K, Hong KS. Association between ST8SIA2 and the risk of Schizophrenia and bipolar I disorder across diagnostic boundaries. PLoS ONE. 2015;10:e0139413.CrossRefPubMedPubMedCentral
75.
Mandelli L, Emiliani R, Porcelli S, Fabbri C, Albani D, Serretti A. Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. Hum Psychopharmacol. 2014;29:388–91.CrossRefPubMed
76.
Chiesa A, Lia L, Alberti S, Lee SJ, Han C, Patkar AA, Pae CU, Serretti A. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. Int J Psychiatry Clin Pract. 2014;18:97–102.CrossRefPubMed
Metadata
Title
Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
Authors
Marco Calabrò
Laura Mandelli
Concetta Crisafulli
Soo-Jung Lee
Tae-Youn Jun
Sheng-Min Wang
Ashwin A. Patkar
Prakash S. Masand
Francesco Benedetti
Changsu Han
Chi-Un Pae
Alessandro Serretti
Publication date
01-10-2018
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 10/2018
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-018-0781-2

Other articles of this Issue 10/2018

Advances in Therapy 10/2018 Go to the issue

Original Research

Predicting Responses to Pregabalin for Painful Diabetic Peripheral Neuropathy Based on Trajectory-Focused Patient Profiles Derived from the First 4 Weeks of Treatment

Original Research

Diagnostic Accuracy of Bronchodilator Response for Asthma in a Population of South China

Correction

Correction to: Expected Budget Impact and Health Outcomes of Expanded Use of Vagus Nerve Stimulation Therapy for Drug-Resistant Epilepsy

Commentary

Does ‘Strong Analgesic’ Equal ‘Strong Opioid’? Tapentadol and the Concept of ‘µ-Load’

Review

An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

Commentary

A Charter to Improve Patient Care in Severe Asthma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits